WO2013066442A3 - Mammalian genes and gene products involved in infection - Google Patents

Mammalian genes and gene products involved in infection Download PDF

Info

Publication number
WO2013066442A3
WO2013066442A3 PCT/US2012/048507 US2012048507W WO2013066442A3 WO 2013066442 A3 WO2013066442 A3 WO 2013066442A3 US 2012048507 W US2012048507 W US 2012048507W WO 2013066442 A3 WO2013066442 A3 WO 2013066442A3
Authority
WO
WIPO (PCT)
Prior art keywords
infection
gene products
mammalian genes
products involved
pathogen
Prior art date
Application number
PCT/US2012/048507
Other languages
French (fr)
Other versions
WO2013066442A2 (en
Inventor
Thomas W. Hodge
Natalie J. Mcdonald
James L. Murray
Michael W. Shaw
Donald H. Rubin
Anthony Sanchez
Original Assignee
Hodge Thomas W
Mcdonald Natalie J
Murray James L
Shaw Michael W
Rubin Donald H
Anthony Sanchez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hodge Thomas W, Mcdonald Natalie J, Murray James L, Shaw Michael W, Rubin Donald H, Anthony Sanchez filed Critical Hodge Thomas W
Publication of WO2013066442A2 publication Critical patent/WO2013066442A2/en
Publication of WO2013066442A3 publication Critical patent/WO2013066442A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2999/00—Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00
    • C12N2999/005—Biological teaching, e.g. a link between protein and disease, new virus causing pandemic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present disclosure relates to mammalian genes and gene products that are involved in infection or are otherwise associated with the life cycle of one or more pathogens. Disclosed herein are methods of reducing infection of a cell by a pathogen, for example to treat or prevent a pathogen infection. Exemplary pathogens include HIV-1, HIV-2, influenza A, Marburg virus and Ebola virus. The disclosure also relates to methods of identifying agents involved in pathogen infection.
PCT/US2012/048507 2011-07-29 2012-07-27 Mammalian genes and gene products involved in infection WO2013066442A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513437P 2011-07-29 2011-07-29
US61/513,437 2011-07-29

Publications (2)

Publication Number Publication Date
WO2013066442A2 WO2013066442A2 (en) 2013-05-10
WO2013066442A3 true WO2013066442A3 (en) 2013-07-18

Family

ID=48192978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/048507 WO2013066442A2 (en) 2011-07-29 2012-07-27 Mammalian genes and gene products involved in infection

Country Status (1)

Country Link
WO (1) WO2013066442A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105396143B (en) * 2014-09-01 2020-06-26 江苏命码生物科技有限公司 MiRNA (micro ribonucleic acid) with specificity of Ebola virus and method for inhibiting Ebola virus through miRNA
US20220252574A1 (en) * 2019-07-22 2022-08-11 University Of Louisville Research Foundation, Inc. Immunomodulatory compositions and methods of using
CN112375758B (en) * 2020-11-17 2022-12-13 中国人民解放军空军军医大学 Anti-hantavirus antisense nucleic acid sequence and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257872A1 (en) * 2002-11-18 2006-11-16 Hodge Thomas W Cell lines and host nucleic acid sequences related to infectious disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257872A1 (en) * 2002-11-18 2006-11-16 Hodge Thomas W Cell lines and host nucleic acid sequences related to infectious disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KRISHNAN ET AL.: "Rab 5 is required for the cellular entry of dengue and West Nile viruses.", J. VIROL., vol. 81, no. 9, 2007, pages 4881 - 4885 *

Also Published As

Publication number Publication date
WO2013066442A2 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
MX346439B (en) Methods and means to modify a plant genome.
EA201690497A3 (en) COMPOSITIONS AND METHODS TO INHIBIT EXPRESSION OF HEPATITIS V VIRUS GENES
MD20140035A2 (en) Method for treating hepatitis C virus
EP4269584A3 (en) Selective antisense compounds and uses thereof
MX2014003889A (en) Anti-viral compounds.
MX2014003979A (en) Modified nucleosides, nucleotides, and nucleic acids, and uses thereof.
WO2012093833A3 (en) Genome engineering via designed tal effector nucleases
WO2013085550A3 (en) V1v2 immunogens
MX2021009554A (en) Production of viruses in cell culture.
IN2015KN00073A (en)
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
TN2014000327A1 (en) Oligonucleotides for modulating gene expression and uses thereof
MX351818B (en) Anti-viral compounds.
AP2013007180A0 (en) Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
MX348785B (en) Methods and means to modify a plant genome at a preselected site.
WO2013066442A3 (en) Mammalian genes and gene products involved in infection
WO2013052095A3 (en) Vaccine
WO2012154271A3 (en) Method and cells for identifying rig-i pathway regulators
EA201270577A1 (en) IMPROVED METHODS OF REVERSE GENETICS FOR THE RESCUE OF VIRUSES
CA2869033C (en) Nucleic acids for nucleic acid amplification
WO2010099169A3 (en) A novel in vitro hiv-1 latency model for screening reactivation agents of hiv-1
CL2013003466A1 (en) Arn construction comprising a sense segment sequence and an antisense of the p0 gene of the genome of the moderate beet yellowing virus (bmyv), a method for inducing tolerance to the bmyv virus.
MX360120B (en) Production of infectious influenza viruses.
PL2643460T3 (en) Methods, compositions, and kits for determining human immunodeficiency virus (hiv)
WO2012174192A3 (en) Method of amplifying a nucleic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12846771

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12846771

Country of ref document: EP

Kind code of ref document: A2